Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 828-832

  Gonelli, Arianna ^a   Radillo, Oriano ^b   Drioli, Sara ^c   Rimondi, Erika ^a   Secchiero, Paola ^a   Maria Bonora, Gian ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Pegylation; Signal transduction; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEGYLATED TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CASP3 PROTEIN, HUMAN; CASPASE 3; HYBRID PROTEIN; MACROGOL DERIVATIVE; MAPK1 PROTEIN, HUMAN; PEGYLATED TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND; TNFSF10 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BONE MARROW; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA; LEUKEMIA CELL LINE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; CELL MOTION; CELL STRAIN HL 60; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; LEUKEMIA; MESENCHYMAL STEM CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84862260904     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9599-8     Document Type: Article

References (21)

1. Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331-340
2. Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates prosurvival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126-135
3. Secchiero P, Zauli G (2008) TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 15:42-48
4. Soria JC, Smit E, Khayat D et al (2010) Phase 1b study of Dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28:1527-1533
5. Kelley SK, Harris LA, Xie D et al (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31-38
6. Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandon E (2004) Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 32:1230-1238
7. Mirandola P, Ponti C, Gobbi G et al (2004) Activated human NK and CD8+ T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAILmediated cytotoxicity. Blood 104:2418-2424
8. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G (2005) TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413-3419
9. Re MC, Zauli G, Gibellini D et al (1993) Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS 7:1049-1055
10. Campioni D, Corallini A, Zauli G, Possati L, Altavilla G, Barbanti-Brodano G (1995) HIV type 1 extracellular tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hum Retrovir 11:1039-1048
11. Secchiero P, Zerbinati C, Rimondi E et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965-1974
12. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S (1996) Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 271:22961-22964
13. Gibellini D, Bassini A, Pierpaoli S et al (1998) Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160:3891-3898
14. Secchiero P, Corallini F, Pandolfi A et al (2006) An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236-2244
15. Secchiero P, Melloni E, Corallini F et al (2008) Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 26:2955-2963
16. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221
17. Veronese F, Pasut GF, Drioli S, Bonora GM (2010) Poly(ethylene glycol)-protein, peptide and enzyme conjugates. In: Reddy LH, Couvreur P (eds) Macromolecular anticancer therapeutics. Springer, New York, pp 265-291
18. Bonora GM, Drioli S (2009) Reactive PEGs for protein conjugation. In: Veronese F (ed) PEGylated protein drugs: basic science and clinical applications. Birkhause Verlag AG (CH), pp 33-45
19. Yamamoto Y, Tsutsumi Y, Yoshioka Y et al (2003) Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 21:546-552
20. Shaunak S, Godwin A, Choi JWet al (2006) Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol 2:312-313
21. Chae SY, Kim TH, Park K et al (2010) Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 9:1719-1729